Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa

Mauricio Lisker-Melman; Adrian M. Di Bisceglie; Stephen J. Usala; Bruce Weintraub; Linda M. Murray; Jay H. Hoofnagle

doi:10.1016/0016-5085(92)90348-3

Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa

Mauricio Lisker-Melman, Adrian M. Di Bisceglie, Stephen J. Usala, Bruce Weintraub, Linda M. Murray, Jay H. Hoofnagle

Research output: Contribution to journal › Article › peer-review

228 Scopus citations

Abstract

Six of 237 (2.5%) patients with chronic viral hepatitis who were treated with recombinant interferon alfa developed thyroid disease while on treatment. Three patients developed hyperthyroidism, two of whom developed detectable levels of thyroid-stimulating immunoglobulin; three patients developed hypothyroidism in association with high titers of antithyroglobulin and/or antimicrosomal antibodies. The thyroid disease did not remit when interferon therapy was stopped, and all six patients required definitive therapy for the thyroid disease. These findings suggest that a small proportion of patients treated with interferon alfa develop autoimmune reactions and can develop autoimmune thyroid disease.

Original language	English
Pages (from-to)	2155-2160
Number of pages	6
Journal	Gastroenterology
Volume	102
Issue number	6
DOIs	https://doi.org/10.1016/0016-5085(92)90348-3
State	Published - Jun 1992

Access to Document

10.1016/0016-5085(92)90348-3

Cite this

@article{0de6b08cae954a6bb25cc591b3500605,

title = "Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa",

abstract = "Six of 237 (2.5%) patients with chronic viral hepatitis who were treated with recombinant interferon alfa developed thyroid disease while on treatment. Three patients developed hyperthyroidism, two of whom developed detectable levels of thyroid-stimulating immunoglobulin; three patients developed hypothyroidism in association with high titers of antithyroglobulin and/or antimicrosomal antibodies. The thyroid disease did not remit when interferon therapy was stopped, and all six patients required definitive therapy for the thyroid disease. These findings suggest that a small proportion of patients treated with interferon alfa develop autoimmune reactions and can develop autoimmune thyroid disease.",

author = "Mauricio Lisker-Melman and {Di Bisceglie}, {Adrian M.} and Usala, {Stephen J.} and Bruce Weintraub and Murray, {Linda M.} and Hoofnagle, {Jay H.}",

year = "1992",

month = jun,

doi = "10.1016/0016-5085(92)90348-3",

language = "English",

volume = "102",

pages = "2155--2160",

journal = "Gastroenterology",

issn = "0016-5085",

number = "6",

}

TY - JOUR

T1 - Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa

AU - Lisker-Melman, Mauricio

AU - Di Bisceglie, Adrian M.

AU - Usala, Stephen J.

AU - Weintraub, Bruce

AU - Murray, Linda M.

AU - Hoofnagle, Jay H.

PY - 1992/6

Y1 - 1992/6

N2 - Six of 237 (2.5%) patients with chronic viral hepatitis who were treated with recombinant interferon alfa developed thyroid disease while on treatment. Three patients developed hyperthyroidism, two of whom developed detectable levels of thyroid-stimulating immunoglobulin; three patients developed hypothyroidism in association with high titers of antithyroglobulin and/or antimicrosomal antibodies. The thyroid disease did not remit when interferon therapy was stopped, and all six patients required definitive therapy for the thyroid disease. These findings suggest that a small proportion of patients treated with interferon alfa develop autoimmune reactions and can develop autoimmune thyroid disease.

AB - Six of 237 (2.5%) patients with chronic viral hepatitis who were treated with recombinant interferon alfa developed thyroid disease while on treatment. Three patients developed hyperthyroidism, two of whom developed detectable levels of thyroid-stimulating immunoglobulin; three patients developed hypothyroidism in association with high titers of antithyroglobulin and/or antimicrosomal antibodies. The thyroid disease did not remit when interferon therapy was stopped, and all six patients required definitive therapy for the thyroid disease. These findings suggest that a small proportion of patients treated with interferon alfa develop autoimmune reactions and can develop autoimmune thyroid disease.

UR - http://www.scopus.com/inward/record.url?scp=0026604957&partnerID=8YFLogxK

U2 - 10.1016/0016-5085(92)90348-3

DO - 10.1016/0016-5085(92)90348-3

M3 - Article

C2 - 1587439

AN - SCOPUS:0026604957

SN - 0016-5085

VL - 102

SP - 2155

EP - 2160

JO - Gastroenterology

JF - Gastroenterology

IS - 6

ER -

Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa

Abstract

Access to Document

Other files and links

Fingerprint

Cite this